CompBrief BY VELARION

Companies Myovant Sciences Ltd.

Myovant Sciences CEO salary & total pay, FY2021: $6.2M

Myovant Sciences (MYOV) CEO salary, fiscal 2021: David Marek was paid a salary of $750,000 and $6,247,509 in total compensation. Free brief. Every figure links to the company’s own filing.

Myovant Sciences Ltd. no longer files a proxy statement; its last pay data is FY2021.

All products and prices

David Marek's complete compensation dossier

A PDF and a CSV sent to your email: David Marek's pay in every fiscal year Myovant Sciences Ltd. reported it, line by line, with David Marek's equity grants and Myovant Sciences Ltd.'s disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$6,247,509CEO David Marek · source
Say-on-pay support91.59%Latest vote · source
CEO vs. named peers36th pct.Against its disclosed peer group

CEO pay, last three years

  • $10,276,517FY2020
  • $6,247,509FY2021

CEO total pay was $6,247,509 in fiscal 2021, down from $10,276,517 in fiscal 2020.

FY2021: salary $750,000 · bonus $0 · stock awards $2,410,027 · option awards $2,407,333

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Myovant Sciences Ltd. in fiscal 2021?
As disclosed, David Marek (Principal Executive Officer) was the highest-paid executive at Myovant Sciences Ltd. in fiscal 2021, with total compensation of $6,247,509.
How does Myovant Sciences Ltd.'s chief executive pay compare to its disclosed peer group?
As disclosed, David Marek's total compensation ranked at the 36th percentile of Myovant Sciences Ltd.'s disclosed peer group.
How did shareholders vote on Myovant Sciences Ltd.'s executive compensation?
As disclosed, 91.59% of shareholders supported Myovant Sciences Ltd.'s executive compensation in the latest say-on-pay vote.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
David Marek$750,000$0$2,410,027$2,407,333$473,000$0$207,149$6,247,509
Principal Executive Officer
Uneek Mehra278,609200,0002,249,9962,283,515142,000010,7525,164,872
Principal Financial Officer
Frank Karbe212,884251,0001,128,9071,152,197270,00001,436,1494,451,137
Former Principal Financial and Accounting Officer
Lauren Merendino461,72101,399,9861,425,545175,00001,4253,463,677
Chief Commercial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2021 totalFY2020 totalFY2019 totalΔ FY2020→2021
David Marek$6,247,509$10,276,517—↓ −4,029,008
Uneek Mehra5,164,872———
Frank Karbe4,451,1372,989,412—↑ +1,461,725
Lauren Merendino3,463,677———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Equity grants and outstanding awards

No plan-based awards are on file for this fiscal year.

Outstanding equity awards at fiscal year-end 2021

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
David MarekOption76,606229,82120.54—
David MarekRSU—167,307—2,228,529
David MarekOption—208,21817.88—
David MarekRSU—134,789—1,795,389
Lauren MerendinoOption—123,30017.88—
Lauren MerendinoRSU—78,299—1,042,943
Uneek MehraOption—165,19221.83—
Uneek MehraRSU—103,069—1,372,879
Director compensation

No director compensation table is on file for fiscal year 2021.

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer$266,200
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline—
Peer group, and who names Myovant Sciences as a peer

Companies that benchmark against MYOV

The list of companies that name MYOV as a peer is temporarily unavailable — recheck shortly.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Myovant Sciences Ltd.2021David Marek$750,000$2,410,027$2,407,333$473,000$6,247,509

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20222022-10-2168,808,3085,909,941407,68991.59%Passed
20212021-11-0572,455,8021,191,20492,33098.26%Passed
20202020-09-1552,028,04714,146,332751,74077.74%Passed
20192019-08-2380,796,510196,86735,45699.76%Passed
20172017-08-18—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20222022-10-2191.59%a
20212021-11-0598.26%b
20202020-09-1577.74%c

a. Approved under the standard stated in the filing — “Abstentions will be counted towards the vote total and will have the same effect as "Against" votes.”.

b. Approved under the standard stated in the filing — “Abstentions will be counted towards the vote total and will have the same effect as "Against" votes.”.

c. Approved under the standard stated in the filing — “Abstentions will be counted towards the vote total and will have the same effect as "Against" votes.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Insider trades since the proxy

No insider equity transactions reported since the proxy statement.

Sources (9 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, David Marek. DEF 14A, filed 2022-07-28. Section “Executive Compensation” · page 32. As printed: 6,247,509. View filing ↗
  • Section 01, Uneek Mehra. DEF 14A, filed 2022-07-28. Section “Executive Compensation” · page 32. As printed: 5,164,872. View filing ↗
  • Section 01, Frank Karbe. DEF 14A, filed 2022-07-28. Section “Executive Compensation” · page 32. As printed: 4,451,137. View filing ↗
  • Section 01, Lauren Merendino. DEF 14A, filed 2022-07-28. Section “Executive Compensation” · page 32. As printed: 3,463,677. View filing ↗
  • Section 06, 2022 vote. Form 8-K, filed 2022-10-21. Item 5.07 · say-on-pay result. As reported: 91.59% (votes for as printed: 68,808,308). View filing ↗
  • Section 06, 2021 vote. Form 8-K, filed 2021-11-08. Item 5.07 · say-on-pay result. As reported: 98.26% (votes for as printed: 72,455,802). View filing ↗
  • Section 06, 2020 vote. Form 8-K, filed 2020-09-17. Item 5.07 · say-on-pay result. As reported: 77.74% (votes for as printed: 52,028,047). View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Myovant Sciences Ltd. (subject), Section 10b CEO total. DEF 14A, filed 2022-07-28. CEO total compensation as printed in Myovant Sciences Ltd.'s own proxy. As printed: 6,247,509. View filing ↗